



Capital increase in connection with exercise of warrants

Ambu A/S issued 419,500 warrants in November 2016. Each warrant entitles the holder to subscribe for one Class B share with a nominal value of DKK 0.50 and 71 individuals participate in the 2016 scheme. The vesting period for the scheme is three years, and the scheme can therefore be exercised in the trading window that opened on 13 November 2019 in connection with Ambu's financial report for 2018/19.

Since 13 November 2019, instructions have been received to exercise warrants as follows:

- 2016 scheme: Five individuals have issued instructions to exercise a total of 40,000 warrants at the agreed exercise price of DKK 77.12 per share with a nominal value of DKK 0.50.

Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 20,000 from DKK 125,904,800 to DKK 125,924,800 through the issue of 40,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 364,500 remaining warrants under the 2016 scheme being held by 61 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 27 November 2019 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

	Number of shares (nominal value DKK 0.50)	Nominal value (DKK)	Voting rights
A shares	34,320,000	17,160,000	343,200,000
B shares	217,529,600	108,764,800	217,529,600
Total	251,849,600	125,924,800	560,729,600

Contact

Michael Højgaard, CFO, tel. +45 4030 4349, email: miho@ambu.com

Ambu A/S
Baltorpbakken 13
2750 Ballerup, Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com

About Ambu

Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Visualisation, Anaesthesia, and Patient Monitoring & Diagnostics. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the Ambu aScope™ – the world's first single-use flexible endoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medtech companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 3,000 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.